ALB/Albumin Lentiviral Activation Particles (h): sc-400269-LAC

Human ALB encodes albumin, the most abundant plasma protein synthesized by hepatocytes, essential for maintaining oncotic pressure and buffering extracellular fluid distribution. Albumin binds and transports fatty acids, bilirubin, steroid hormones, and a wide range of xenobiotics, supporting hepatic metabolic homeostasis and systemic nutrient delivery. ALB expression is tightly linked to hepatocyte differentiation and liver-specific transcriptional programs, including HNF and C/EBP-regulated networks that coordinate lipid handling, detoxification, and secretory function. Dysregulated albumin production is widely used as a molecular indicator of impaired hepatic synthetic capacity and altered liver physiology in diverse liver injury and metabolic disease research settings.

ALB/Albumin Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient ALB upregulation across a broader range of human cell types.

ALB/Albumin Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the ALB transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous ALB/Albumin expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native ALB genomic locus and regulatory architecture.

The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.